Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Glatiramer Acetate in Active Secondary Progressive MS
NCT03315923Phase 3Completed
- Start
- Dec 2017
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in secondary-progressive multiple sclerosis (SPMS). Started Dec 2017; status: completed.
02
Drugs
rituximab
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT03315923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03315923.